BioCentury | May 8, 2020
Regulation

$8B Loxo deal yields first drug with approval of Lilly’s targeted lung cancer therapy

...six months. In medullary thyroid cancer, the ORR was 69% for patients previously treated with cabozantinib...
BioCentury | Apr 20, 2020
Product Development

Opdivo-Cabometyx combo improves PFS by 49%, OS by 40% in first-line RCC

...and partners Bristol Myers Squibb and Ipsen said the combination of Opdivo nivolumab plus Cabometyx cabozantinib...
...carcinoma patients. The Phase III CheckMate -9ER trial of PD-1 inhibitor Opdivo plus kinase inhibitor Cabometyx...
...#), nivolumab (Generic), Opdivo (Other) Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx...
BioCentury | Feb 11, 2020
Product Development

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

...augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib...
...in tablet form as Cabometyx to treat kidney and liver cancer and as the capsule Cometriq...
...receptor 2 Paul Bonanos, Associate Editor Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx...
BioCentury | Nov 22, 2019
Clinical News

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

...Therapy in Decades ”). Roche and Exelixis Inc. (NASDAQ:EXEL) are also testing Tecentriq plus Cometriq cabozantinib...
...untreated advanced HCC. The study has an estimated primary completion date of Aug. 1, 2020. Cometriq...
BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...poor uptake of NGS tests, oncologists treat them with off-label Cabometyx cabozantinib from Exelixis Inc. Cabometyx...
...with c-MET, VEGFR-1, VEGFR-2 and VEGFR-3. In an open-label trial in previously treated NSCLC patients, Cabometyx...
...are sometimes treated off-label with Pfizer Inc.’s Xalkori crizotinib, a c-Met and ALK inhibitor, or Cabometyx...
BioCentury | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

...to anti-HER2 antibody trastuzumab plus CDK4/CDK6 inhibitor palbociclib. The immature myeloid cells highly expressed Cometriq cabozantinib...
BioCentury | May 16, 2019
Company News

May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more

...would be eligible for undisclosed milestones plus royalties (see “Exelixis to Fuel Pipeline Growth with Cabometyx...
BioCentury | May 10, 2019
Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

...On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the...
...FDA approved Cabometyx cabozantinib to treat second-line RCC 5/23/16 - Ph II CABOSUN trial of cabozantinib...
...receptor 2 Stephen Hansen, Associate Editor Cometriq (Brand), Cabometyx (Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx...
BioCentury | Feb 22, 2019
Clinical News

Keytruda misses survival endpoints in Phase III HCC trial

...ClinicalTrials.gov, the trial's estimated primary completion date is in December. Last month, FDA approved Cabometyx cabozantinib...
...Nexavar. That approval was based on data from the Phase III CELESTIAL trial, in which Cabometyx...
...The drug is an inhibitor of AXL, c-MET, FLT1, VEGFR-2 and FLT-4 (see “FDA Approves Cabometyx...
BioCentury | Feb 20, 2019
Clinical News

Keytruda misses survival endpoints in Phase III HCC trial

...ClinicalTrials.gov, the trial's estimated primary completion date is in December. Last month, FDA approved Cabometyx cabozantinib...
...Nexavar. That approval was based on data from the Phase III CELESTIAL trial, in which Cabometyx...
...The drug is an inhibitor of AXL, c-MET, FLT1, VEGFR-2 and FLT-4 (see “FDA Approves Cabometyx...
Items per page:
1 - 10 of 296